from
S&P Credit Research1387 word report
published Oct 13, 2009
Price
$175.00 available for immediate download
Report Overview
Search Inside
About
S&P Credit Research
| Abstract: | The strong investment-grade rating on Abbott Park, Ill.-based Abbott Laboratories reflects the company's solid positions in a number of diverse health care segments, its excellent financial profile, and robust discretionary cash flow. Abbott continues to maintain a broad product portfolio with solid positions in pharmaceuticals, nutritionals, diagnostics and vascular devices. These positions are often strengthened through acquisitions. For example, its presence in the ophthalmic market was established through the early 2009 purchase of Advanced Medical Optics (AMO). The recently announced acquisition of the pharmaceutical business of Belgium-based Solvay SA adds a number of products to the pharmaceutical portfolio, while eliminating a significant royalty payment. Abbott's pharmaceutical segment underpins its excellent business risk profile, accounting for a majority of earnings and
|
| Brief Excerpt: | RESEARCH Ratings Definitions Summary: Abbott Laboratories Publication date: 13-Oct-2009 Primary Credit Analyst: Arthur Wong, New York (1) 212-438-7870; arthur_wong@standardandpoors.com Secondary Credit Analyst: Vivek Vishwanathan,...
|
| Report Type: | Summary
|
| Ticker: | ABT
|
| Issuer: | Abbott Laboratories
|
| GICS: | Pharmaceuticals (35202010)
|
| Sector: | Global Issuers
|
| Country: | United States
|
| Region: | United States
|
| Free Sample: |
Click Here to Download
|
| Format: | | HTML |  |
|
S&P Credit Research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.
Also from S&P Credit Research
- Abbott Laboratories $400.00
Well-established positions in a broad range of health care markets; Strong product portfolio, driven by the success of Humira and the Xience stent platform; Limited exposure to patent expirations over the next three years; and Conservative ...
- Bulletin: Abbott Laboratories Ratings Unaffected By $6.6 Billion Purchase Of Solvay Unit $100.00
NEW YORK (Standard&Poor's) Sept. 28, 2009--Standard&Poor's Ratings Services today said that the announcement by Abbott Laboratories (AA/Stable/A-1+) that it plans to buy Belgium-based Solvay SA's pharmaceutical business for €4.5 billion (roughly ...
- Abbott Laboratories 'AA' Corporate Credit, Other Ratings Affirmed; Senior Unsecured Debt Rated 'AA' $100.00
NEW YORK (Standard&Poor's) Feb. 26, 2009--Standard&Poor's Ratings Services said today that it assigned its 'AA' senior unsecured debt ratings to Abbott Park, Ill.-based Abbott Laboratories' 10- and 30-year senior unsecured notes, to be issued ...
- Research Update: Abbott Laboratories Senior Unsecured Debt Rated 'AA'; 'AA' Corporate Credit, Other Ratings Affirmed $175.00
On Feb. 26, 2009, Standard&Poor's Ratings Services said that it assigned its 'AA' senior unsecured debt ratings to Abbott Park, Ill.-based Abbott Laboratories' 10- and 30-year senior unsecured notes, to be issued in two tranches. At the same ...
- Research Update: Abbott Laboratories Ratings Affirmed After AMO Purchase; Outlook Remains Stable $175.00
On Jan. 12, 2009, Standard&Poor's Ratings Services affirmed its 'AA' corporate credit and all other ratings on Abbott Park, Ill.-based Abbott Laboratories, following the company's announcement of its $2.8 billion purchase of Santa Ana, Calif.-based ...
- Abbott Laboratories Ratings Affirmed; Outlook Remains Stable $100.00
Standard&Poor's Ratings Services said today that it affirmed its 'AA' corporate credit and all other ratings on Abbott Park, Ill.-based Abbott Laboratories, following the company's announcement of its $2.8 billion purchase of Santa Ana, Calif.-based ...
- Abbott Laboratories Ratings Affirmed Following $5 Billion Share Repurchase; Outlook Stable $100.00
NEW YORK (Standard&Poor's) Oct. 13, 2008--Standard&Poor's Ratings Services said today that it affirmed its ratings on Abbott Laboratories, following the company's announcement of its $5 billion share repurchase program. The outlook remains ...
- Research Update: Abbott Laboratories Ratings Affirmed Following $5 Billion Buyback; Outlook Stable $175.00
On Oct. 13, 2008, Standard&Poor's Ratings Services affirmed its ratings on Abbott Laboratories, following the company's announcement of its $5 billion share repurchase program. The outlook remains stable. Abbott continues to maintain conservative ...
